The effect of CoQ10 supplementation on lipoproteins and ICAM, IL6, and plasma fibrinogen in hyperlipedimic patients with myocardial infarction.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138811192709N4

Enrollment

Registered

2010-05-04

Start date

2010-04-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complications and ill-defined descriotions of heart disease. Complications and ill-defined descriotions of heart disease, Certain current complications following acute myocardial infarction

Interventions

Intervention 1: CoQ10, 200 mg daily for 3 months. Intervention 2: Placebo for 3 months.

Treatment - Drugs

Placebo

CoQ10, 200 mg daily for 3 months

Placebo for 3 months

Eligibility

Sex/Gender

All

Age

35 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 35-70, triglyceride between 15o and 400mg/dl, cholesterol more than 150mg/dl, BMI more than 30KG/M2 Exclusion criteria: use of vitamin or w3 supplements, use of anti inflammatory non-steroidal drugs, presence of inflammatory diseases, renal, or hepatic diseases, or diabetes, change in physical activity, antiquagolants or other drugs dosages

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
LDL-cholesterol. Timepoint: before intervention,3 months after intervention. Method of measurement: friedwald formula.;HDL-c. Timepoint: before intervention and 3 months after inter vention. Method of measurement: enzymatic method(kit).;Plasma fibrinogen. Timepoint: before intrervention and 3 months after intervention. Method of measurement: enzymatic method(kit).;Interlukine-6. Timepoint: before intervention and 3 months after inter vention. Method of measurement: elisa test.;Intera cellular adhesion molecules. Timepoint: before interventon and 3 months after intervention. Method of measurement: ELISA test.;Total cholesterol. Timepoint: before intervention and 3 months after inter vention. Method of measurement: enzymatic method(kit).	—

Measure

Time frame

LDL-cholesterol. Timepoint: before intervention,3 months after intervention. Method of measurement: friedwald formula.;HDL-c. Timepoint: before intervention and 3 months after inter vention. Method of measurement: enzymatic method(kit).;Plasma fibrinogen. Timepoint: before intrervention and 3 months after intervention. Method of measurement: enzymatic method(kit).;Interlukine-6. Timepoint: before intervention and 3 months after inter vention. Method of measurement: elisa test.;Intera cellular adhesion molecules. Timepoint: before interventon and 3 months after intervention. Method of measurement: ELISA test.;Total cholesterol. Timepoint: before intervention and 3 months after inter vention. Method of measurement: enzymatic method(kit).

—

Secondary

Measure	Time frame
Prevention of recurrent of myocardial infarction. Timepoint: 3 months after intrevention. Method of measurement: by analysis of data from lipoprotein and other biochemical parameters.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026